Literature DB >> 1638695

Chemoprevention of mammary carcinogenesis by hydroxylated derivatives of d-limonene.

P L Crowell1, W S Kennan, J D Haag, S Ahmad, E Vedejs, M N Gould.   

Abstract

The monoterpene d-limonene has been shown to an effective, non-toxic chemopreventive agent in mammary and other rodent tumor models. The studies reported here investigated structure-activity relationships among limonene and three hydroxylated derivatives in the prevention of dimethylbenz[a]anthracene (DMBA)-induced mammary cancer. Rats were fed control or 1% limonene, carveol, uroterpenol or sobrerol diets from 2 weeks before to one week after carcinogen administration. Carveol, uroterpenol and sobrerol significantly prolonged tumor latency and decreased tumor yield. Sobrerol was the most potent of the monoterpenes tested, decreasing tumor yield to half that of the control, a level previously achieved with 5% limonene diets. Excretion of radioactivity from [3H]DMBA was doubled in rats fed 5% limonene and nearly tripled in rats fed 1% sobrerol. Sobrerol is thus 5-fold more potent than limonene in both enhancing carcinogen excretion and in preventing tumor formation. These data demonstrate that hydroxylation of monoterpenes affects chemopreventive potential, with 2 hydroxyl groups greater than 1 greater than 0. Sobrerol, carveol and uroterpenol are novel cancer chemopreventive agents with little or no toxicity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1638695     DOI: 10.1093/carcin/13.7.1261

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  16 in total

Review 1.  Hormone-induced protection against breast cancer.

Authors:  Lakshmi Sivaraman; Daniel Medina
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-01       Impact factor: 2.673

Review 2.  [Current aroma research].

Authors:  P Schreier
Journal:  Naturwissenschaften       Date:  1995-01

3.  Plasma metabolomic profiles of breast cancer patients after short-term limonene intervention.

Authors:  Jessica A Miller; Kirk Pappan; Patricia A Thompson; Elizabeth J Want; Alexandros P Siskos; Hector C Keun; Jacob Wulff; Chengcheng Hu; Julie E Lang; H-H Sherry Chow
Journal:  Cancer Prev Res (Phila)       Date:  2014-11-11

4.  Determination of d-limonene in adipose tissue by gas chromatography-mass spectrometry.

Authors:  Jessica A Miller; Iman A Hakim; Cynthia Thomson; Patricia Thompson; H-H Sherry Chow
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2008-06-06       Impact factor: 3.205

5.  Identification of metabolites of the antitumor agent d-limonene capable of inhibiting protein isoprenylation and cell growth.

Authors:  P L Crowell; S Lin; E Vedejs; M N Gould
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 6.  Aromatherapy as an adjuvant treatment in cancer care--a descriptive systematic review.

Authors:  Katja Boehm; Arndt Büssing; Thomas Ostermann
Journal:  Afr J Tradit Complement Altern Med       Date:  2012-07-01

7.  Human breast tissue disposition and bioactivity of limonene in women with early-stage breast cancer.

Authors:  Jessica A Miller; Julie E Lang; Michele Ley; Ray Nagle; Chiu-Hsieh Hsu; Patricia A Thompson; Catherine Cordova; Amy Waer; H-H Sherry Chow
Journal:  Cancer Prev Res (Phila)       Date:  2013-04-03

8.  Human metabolism of the experimental cancer therapeutic agent d-limonene.

Authors:  P L Crowell; C E Elson; H H Bailey; A Elegbede; J D Haag; M N Gould
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

9.  Selective Preparation of trans-Carveol over Ceria Supported Mesoporous Materials MCM-41 and SBA-15.

Authors:  Martina Stekrova; Narendra Kumar; Päivi Mäki-Arvela; Oleg V Ardashov; Konstantin P Volcho; Nariman F Salakhutdinov; Dmitry Yu Murzin
Journal:  Materials (Basel)       Date:  2013-05-17       Impact factor: 3.623

10.  Modulation of the mevalonate pathway and cell growth by pravastatin and d-limonene in a human hepatoma cell line (Hep G2).

Authors:  S Kawata; T Nagase; E Yamasaki; H Ishiguro; Y Matsuzawa
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.